Fig. 3From: Characterization and dosimetric predictors for absolute lymphocyte count changes during neoadjuvant chemoradiotherapy with or without pembrolizumab for esophageal squamous cell carcinoma: an analysis of a prospective cohortComparison the ALC nadir between pCR and non-pCR groupsBack to article page
